Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hans Carl Hasselbalch, Morten Orebo Holmström
Seminars in Immunopathology (2018) Vol. 41, Iss. 1, pp. 5-19
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Harnessing cytokines and chemokines for cancer therapy
David Propper, Frances R. Balkwill
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 237-253
Closed Access | Times Cited: 617
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, et al.
The Lancet Haematology (2020) Vol. 7, Iss. 3, pp. e196-e208
Open Access | Times Cited: 275
Current Perspectives in Cancer Immunotherapy
Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, et al.
Cancers (2019) Vol. 11, Iss. 10, pp. 1472-1472
Open Access | Times Cited: 188
Chitin and Chitosan: Prospective Biomedical Applications in Drug Delivery, Cancer Treatment, and Wound Healing
Parnian Baharlouei, M. Azizur Rahman
Marine Drugs (2022) Vol. 20, Iss. 7, pp. 460-460
Open Access | Times Cited: 141
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Jean‐Jacques Kiladjian, Christoph Klade, Pencho Georgiev, et al.
Leukemia (2022) Vol. 36, Iss. 5, pp. 1408-1411
Open Access | Times Cited: 79
JAK2 V617F allele burden in polycythemia vera: burden of proof
Alison R. Moliterno, Hannah Kaizer, Brandi Reeves
Blood (2023) Vol. 141, Iss. 16, pp. 1934-1942
Open Access | Times Cited: 59
The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies
Brianna M. Craver, Kenza El Alaoui, Robyn M. Scherber, et al.
Cancers (2018) Vol. 10, Iss. 4, pp. 104-104
Open Access | Times Cited: 102
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Haematologica (2019) Vol. 105, Iss. 9, pp. 2262-2272
Open Access | Times Cited: 90
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Daniel Arthur Corpuz Fisher, Jared S. Fowles, Amy Zhou, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 82
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
Albert Qin, Raymond Urbanski, Lennex Hsueh‐Lin Yu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 25
Interferons in the treatment of myeloproliferative neoplasms
Pankit Vachhani, John O. Mascarenhas, Prithviraj Bose, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 12
Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms
Jingyuan Tong, Ting Sun, Shihui Ma, et al.
Cell stem cell (2021) Vol. 28, Iss. 3, pp. 502-513.e6
Open Access | Times Cited: 47
Alginate-Chitosan Biodegradable and Biocompatible Based Hydrogel for Breast Cancer Immunotherapy and Diagnosis: A Comprehensive Review
Pratikshya Patra, Tarun Kumar Upadhyay, Nawaf Alshammari, et al.
ACS Applied Bio Materials (2024) Vol. 7, Iss. 6, pp. 3515-3534
Open Access | Times Cited: 8
Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
Morten Andersen, Zamra Sajid, Rasmus Kristoffer Pedersen, et al.
PLoS ONE (2017) Vol. 12, Iss. 8, pp. e0183620-e0183620
Open Access | Times Cited: 59
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Sara Galimberti, Chiara Baldini, Claudia Baratè, et al.
Pharmacological Research (2020) Vol. 157, pp. 104866-104866
Open Access | Times Cited: 42
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 41
Moving toward disease modification in polycythemia vera
Jan Philipp Bewersdorf, Joan How, Lucia Masárová, et al.
Blood (2023) Vol. 142, Iss. 22, pp. 1859-1870
Closed Access | Times Cited: 16
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Jean‐Jacques Kiladjian, Francisca Ferrer‐Marín, Haifa Kathrin Al‐Ali, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2299-2310
Open Access | Times Cited: 6
Cancer biotherapy: review and prospect
Qi Liu, Hu Ma
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
Vibe Skov
Cancers (2020) Vol. 12, Iss. 8, pp. 2194-2194
Open Access | Times Cited: 35
New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
Hans Carl Hasselbalch, Richard T. Silver
HemaSphere (2021) Vol. 5, Iss. 12, pp. e645-e645
Open Access | Times Cited: 25
Neutrophil–lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera
Seong Soon Kwon, Seug Yun Yoon, Sun Young Jeong, et al.
Nutrition Metabolism and Cardiovascular Diseases (2022) Vol. 32, Iss. 8, pp. 1913-1916
Closed Access | Times Cited: 18
Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment
Aleksander Gryciuk, Marta Rogalska, Joanna Baran, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1947-1947
Open Access | Times Cited: 10
Biomarkers in Immunology: Their Impact on Immune Function and Response
Deepika Kaushik, Baojun Xu, Mukul Kumar
Advances in Biomarker Sciences and Technology (2025)
Open Access
CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents
Nungruthai Nilsri, Rujira Mekchaaum, Supaporn Kalasin, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 10, pp. 4600-4600
Open Access
Page 1 - Next Page

Scroll to top